v3.26.1
Product Revenue
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Product Revenue Product Revenue
The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA® and TEVIMBRA® in the U.S., China, EU, and other regions; XGEVA®, BLINCYTO® and KYPROLIS® in China under a license from Amgen; and POBEVCY® in China under a license from Bio-Thera.
The table below presents the Company’s net product revenue for the three and six months ended June 30, 2026 and 2025:
Three Months EndedSix Months Ended
June 30,June 30,
2026202520262025
$$$$
Product revenue – gross2,205,600 1,657,838 4,099,089 3,057,904 
Less: rebates and sales returns(525,806)(355,762)(931,966)(647,298)
Product revenue – net1,679,794 1,302,076 3,167,123 2,410,606 
The following table disaggregates net product revenue by product for the three and six months ended June 30, 2026 and 2025:
Three Months EndedSix Months Ended
June 30,June 30,
2026202520262025
$$$$
BRUKINSA®
1,247,640 949,840 2,342,483 1,741,504 
TEVIMBRA®
228,515 193,524 434,756 364,688 
XGEVA®
104,499 81,318 194,419 151,741 
BLINCYTO®
36,537 25,587 70,572 49,493 
KYPROLIS®
15,147 19,416 32,118 39,144 
POBEVCY®
9,633 11,242 21,760 24,987 
Other37,823 21,149 71,015 39,049 
Total product revenue – net1,679,794 1,302,076 3,167,123 2,410,606 
The following table presents the roll-forward of accrued revenue rebates and returns for the six months ended June 30, 2026 and 2025:
Rebates, Returns and Other DeductionsContra AR AccrualsTotal
$$
Balance at December 31, 2025
398,533 79,126 477,659 
Accrual449,474 482,492 931,966 
Payments(362,137)(499,012)(861,149)
Balance at June 30, 2026
485,870 62,606 548,476 
Balance at December 31, 2024
235,600 50,699 286,299 
Accrual283,525 363,773 647,298 
Payments(221,808)(361,633)(583,441)
Balance at June 30, 2025
297,317 52,839 350,156